FDA Grants Priority Review To BeOne Medicines' Supplemental Biologics License Application For Tevimbra (Tislelizumab) In Combination With Ziihera (Zanidatamab) And Chemotherapy For Untreated Unresectable Locally Advanced/Metastatic HER2-positive Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging disease
Results from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma
Login to comment